Pharmacoeconomic analysis of three regimens for the treatment of pancreatic cancer based on Markov model
Objective To provide evidence-based basis for clinical medication by establishing a Markov model to evaluate the pharma-coeconomics of three treatment regimens for pancreatic cancer.Methods A Markov model was established with reference to drug prices,treatment costs,health utility values,and state transition probabilities to evaluate the effectiveness and economics of the three regimens in the First Hospital of Lanzhou University from June 2017 to May 2022,and conduct sensitivity analysis.Results The results of the Markov model simulation and back-multiplication analysis showed that after 60 cycles(5 years),the cost-effectiveness ratio of gemcitabine combined with albumin-bound paclitaxel(AG)was 437 903.43 yuan/11.80 QALMs,the cost-effectiveness ratio of gemcitabine combined with capecitabine(GX)was 162 234.52 yuan/6.58 QALMs,and the cost-effectiveness ratio of gemcitabine combined with 1-tegrioxaban(GS)was 429 029.92 yuan/15.64 QALMs.Com-pared with the GX regimen,the cost of the AG regimen was 275 668.91 yuan higher,the effect was 5.22 QALMs higher,but the ICER was negative,which was in an absolute disadvantage;the effect of the GS regimen was 9.06 QALMs higher than that of the GX regimen,and the ICER was positive.Conclusion From the perspective of cost-effectiveness,the AG regimen has the highest cost and relatively poor treatment effect,putting it at an absolute disadvantage;the GS regimen is more effective than the GX regimen and has a positive ICER,but the cost is higher,the GX regimen is the preferred regimen.From the perspective of pharmacoeconomics,the GS regimen and the GX regimen are more cost-effective than the AG regimen,patients can achieve longer survival and better quality of life after receiving treatment,thus improving the overall economic benefits.In practical applications,the best treatment regimen needs to be formulated based on the patient's specific situation and the doctor's professional advice.
万方数据
